Академический Документы
Профессиональный Документы
Культура Документы
CKD-5"
Paolo Raggi.
Professor of Medicine. Section of Cardiology.
Tulane University Health Sciences Center. New Orleans, LA,
USA
praggi@tulane.edu
End stage renal disease is associated with hyperphosphatemia and hyperparathyroidism
that often results in soft-tissue calcification. Indeed, arterial calcification is particularly
common and associated in advanced renal failure stages (CKD-V). 1-4 Recent studies have
implicated the ingestion of calcium salts and/or the inevitable metabolic consequences of
this therapy such as elevated serum calcium, hypercalcemic episodes, or suppression of
parathyroid hormone as possible causative factors.3-7CKD patients are at high risk for
cardiovascular disease and suffer from sudden death or myocardial infarction with much
higher frequency than non-uremic individuals.
Though at entry in a dialysis program, most patients present a high burden of risk factors
such as hyperlipidemia, diabetes mellitus, and hypertension, cardiovascular disease in
CRF is explained by traditional risk factors only in part. 8
Indeed, recent evidence suggests that some of the risk may be associated with
abnormalities of mineral metabolism such as hyperphosphatemia and an elevated
calcium-phosphorus (Ca x P) product. 9. Though many patients with end-stage renal
disease (ESRD) are in positive calcium balance, their bone tissue is paradoxically unable
to handle the calcium load provided through calcium-based phosphate binders, dialysate
and diet. Indeed, uremic osteodystrophy comprises 2 forms of bone disease: low turnover
and high turnover bone disease. In the former state, bone is unable to handle calcium and
there is minimal accretion of this mineral in the bone tissue. 10 In high turnover bone
disease calcium is avidly absorbed by the bone but it is also rapidly removed. The endresult in either case is an excess availability of calcium in the circulation with the
possibility to develop metastatic calcification of cardiovascular tissues as well as other
soft tissues. Therefore, an effective control of serum phosphorus levels and Ca x P
product appears to be very important to potentially reduce cardiovascular risk and
improve bone health in CKD.
suspected coronary artery disease. 11 Coronary, aortic and valvular calcification occurs at
an early stage in CKD patients and even pediatric uremic subjects show extensive
vascualar calcifications.
In 1988, Rostand and colleagues examined 43 dialysis patients using energy subtraction
radiography to measure myocardial calcium content. They found that the dialysis patients
had significantly higher myocardial calcium content than control subjects The process of
vascular calcification is not entirely passive, as it is now believed to be an active process
of mineral deposition resembling bone formation that can be initiated and promoted by
hyperphosphatemia, hypercalcemia and hyperlipidemia. The combination of excess
calcium load and elevated phosphorus levels in CKD patients causes a rise in the Ca x P
product that may favor deposition of calcium in the soft tissues. It should be recognized
that calcium in the atherosclerotic plaque accumulates mainly in the sub-intimal space
and that CKD patients have an extensive plaque burden. However, extensive calcification
of the medial layers of the coronary arteries and aorta are also possible and likely
contribute to the extreme degree of calcification noted in this patient population.
progression of the calcification score of the aorta (median increase 28%) and coronary
arteries (median increase 25%), while the sevelamer (Renagel) treated patients showed
no change from baseline in either vascular territory (median increase 6% and 5%
respectively,Figure 2 and 3).
Seventy-three volunteers from the original cohort continued the study for 12 more
months of randomization (Figure 1).At the end of 24 months of follow-up, the
calcification progression in the aorta and coronary arteries had further magnified in
patients treated with calcium salts reaching highly statistically significant values (82%
and 61% increase, respectively; P<0.0001 from baseline). The patients treated with
sevelamer (Renagel) again showed no significant change from baseline (20% and 7%,
respectively, Figure 4).
In
view of the likely interaction of vascular and bone disease, in the extension trial the
investigators also conducted an analysis of the change in bone density of the thoracic
spine in the 2 treatment groups by means of CT densitometry. The patients treated with
calcium salts showed a significant loss in trabecular bone density (-7%) and a nonsignificant decrease in cortical bone density (-2%). On the contrary, patients treated with
sevelamer (Renagel) showed a significant increase in trabecular bone density (+5%)
and a non-statistically significant increase (+2%) in cortical bone density (Figure 5).
Conclusions
It has been suggested that inadequate management of calcium and phosphorus in CKD-V
is an independent predictor of cardiovascular morbidity and mortality in this patient
population. Both population based and CKD specific analyses point at an important
interaction between bone and vascular health. Changess in management in calcium and
phosphorus management directed to avoid directed at avoiding excess calcium load may
reduce the risk of disease progression in both fields. Efforts to maintain Strict a strict
control of the efforts to maintain serum phosphorus below 5.5 mg/dL, serum calcium
below 9.5 mg/dl and Ca x P product below 55 mg 2/dL2 have been recommended in an
attempt to reduce the risks of uremic calcification, cardiovascular disease, and cardiac
death. Sevelamer (Renagel), a calcium-free phosphate binder, provides an important
option for the management of dialysis patients at risk for cardiovascular calcification.
References:
1. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed
tomography in the evaluation of cardiac calcification in chronic dialysis
patients. Am J Kidney Dis 1996;27:394-401